|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 35/768 | |
| A61K 35/76 | |||
| C07K 16/30 | |||
| A61K 39/395 | |||
| A61P 35/00 | |||
| A61K 39/12 |
| (11) | Patento numeris | 2661278 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 12732263.4 |
| Europos patento paraiškos padavimo data | 2012-01-04 | |
| (97) | Europos patento paraiškos paskelbimo data | 2013-11-13 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2019-06-19 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2012/020173 |
| Data | 2012-01-04 |
| (87) | Numeris | WO 2012/094386 |
| Data | 2012-07-12 |
| (30) | Numeris | Data | Šalis |
| 201161429622 P | 2011-01-04 | US |
| (72) |
KIRN, David, US
BELL, John, CA
BREITBACH, Caroline, US
MOON, Anne, US
HWANG, Tae-Ho, KR
LEE, Yu Kyoung, KR
KIM, Mi-kyung, KR
|
| (73) |
SillaJen Biotherapeutics, Inc.,
450 Sansome Street, Suite 650, San Francisco, CA 94111,
US
Sillajen, Inc., 307 Hyowon IC Building Pusan National University San 30, Busan 609-735, KR |
| (54) | TUMOR SPECIFIC COMPLEMENT DEPENDENT CYTOTOXICITY (CDC) ANTIBODIES GENERATED BY ADMINISTRATION OF ONCOLYTIC VACCINIA VIRUS, FOR USE IN THE TREATMENT OF CANCER |
| TUMOR SPECIFIC COMPLEMENT DEPENDENT CYTOTOXICITY (CDC) ANTIBODIES GENERATED BY ADMINISTRATION OF ONCOLYTIC VACCINIA VIRUS, FOR USE IN THE TREATMENT OF CANCER |